Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Injectable Drug Delivery Conference

The SAE Injectable Drug Delivery Conference returns in 2025, serving as a specialised forum for senior technical professionals from leading pharmaceutical companies to explore the [...]

Go to Top